Fulvestrant
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
Product Name
CAS Number
129453-61-8
Therapeutic Class
Antineoplastic Agents; Hormonal Estrogen Antagonists
Dosage Form
Parenteral injection for IM use only, 50 mg/mL
Availability
Commercial
Regulatory Status
USDMF, CEP
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
